Characterisation and Sensitivity of a Canine Mast Cell Tumour Line to Oncolytic Viruses.

IF 2.3 2区农林科学 Q1 VETERINARY SCIENCES

Veterinary and comparative oncology Pub Date : 2024-11-11 DOI:10.1111/vco.13024

Yeganeh Mehrani, Julia E Kakish, Christina Napoleoni, Jennifer Jane Thompson, Jason P Knapp, Jessica A Minott, Jacob G E Yates, Deirdre Stuart, Brenda L Coomber, Robert A Foster, Byram W Bridle, Khalil Karimi

{"title":"Characterisation and Sensitivity of a Canine Mast Cell Tumour Line to Oncolytic Viruses.","authors":"Yeganeh Mehrani, Julia E Kakish, Christina Napoleoni, Jennifer Jane Thompson, Jason P Knapp, Jessica A Minott, Jacob G E Yates, Deirdre Stuart, Brenda L Coomber, Robert A Foster, Byram W Bridle, Khalil Karimi","doi":"10.1111/vco.13024","DOIUrl":null,"url":null,"abstract":"<p><p>Canine mast cell tumours (MCTs) are one of the most common skin cancers of dogs. Surgical removal is the primary treatment, but recurrence and metastasis can occur even with low-grade tumours. As a result, new treatment strategies are being sought. We tested the potential of several oncolytic viruses (OVs) to infect and kill a cell line isolated from a canine MCT. Employing a resazurin-based metabolic assay and flow cytometry technology, we used recombinant vesicular stomatitis virus (rVSV-Δm51), avian orthoavulavirus-1 (AOaV-1), and Orf viruses in our assessment. Our study aimed to evaluate the potential of oncolytic virotherapy in treating canine cancers. We found that MCT-1 cells showed different sensitivities to the OVs, with rVSV-Δm51 showing the most promising results in vitro. These findings suggest that further investigation into using OVs for treating canine MCTs is needed, although clinical efficacy is yet to be determined.</p>","PeriodicalId":23693,"journal":{"name":"Veterinary and comparative oncology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary and comparative oncology","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.1111/vco.13024","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Canine mast cell tumours (MCTs) are one of the most common skin cancers of dogs. Surgical removal is the primary treatment, but recurrence and metastasis can occur even with low-grade tumours. As a result, new treatment strategies are being sought. We tested the potential of several oncolytic viruses (OVs) to infect and kill a cell line isolated from a canine MCT. Employing a resazurin-based metabolic assay and flow cytometry technology, we used recombinant vesicular stomatitis virus (rVSV-Δm51), avian orthoavulavirus-1 (AOaV-1), and Orf viruses in our assessment. Our study aimed to evaluate the potential of oncolytic virotherapy in treating canine cancers. We found that MCT-1 cells showed different sensitivities to the OVs, with rVSV-Δm51 showing the most promising results in vitro. These findings suggest that further investigation into using OVs for treating canine MCTs is needed, although clinical efficacy is yet to be determined.

查看原文本刊更多论文

犬肥大细胞瘤系的特征及对溶瘤病毒的敏感性

犬肥大细胞瘤（MCT）是犬最常见的皮肤癌之一。手术切除是主要的治疗方法，但即使是低级别肿瘤也会出现复发和转移。因此，人们正在寻求新的治疗策略。我们测试了几种溶瘤病毒（OV）感染和杀死从犬 MCT 分离出来的细胞系的潜力。利用基于利马嗪的代谢测定法和流式细胞术技术，我们在评估中使用了重组水泡性口炎病毒（rVSV-Δm51）、禽正粘病毒-1（AOaV-1）和Orf病毒。我们的研究旨在评估溶瘤病毒疗法治疗犬类癌症的潜力。我们发现，MCT-1细胞对OV表现出不同的敏感性，其中rVSV-Δm51在体外显示出最有希望的结果。这些研究结果表明，尽管临床疗效尚有待确定，但有必要进一步研究使用 OVs 治疗犬 MCT。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Veterinary and comparative oncology 农林科学-兽医学

CiteScore

4.80

自引率

9.50%

发文量

审稿时长

>24 weeks

期刊介绍： Veterinary and Comparative Oncology (VCO) is an international, peer-reviewed journal integrating clinical and scientific information from a variety of related disciplines and from worldwide sources for all veterinary oncologists and cancer researchers concerned with aetiology, diagnosis and clinical course of cancer in domestic animals and its prevention. With the ultimate aim of diminishing suffering from cancer, the journal supports the transfer of knowledge in all aspects of veterinary oncology, from the application of new laboratory technology to cancer prevention, early detection, diagnosis and therapy. In addition to original articles, the journal publishes solicited editorials, review articles, commentary, correspondence and abstracts from the published literature. Accordingly, studies describing laboratory work performed exclusively in purpose-bred domestic animals (e.g. dogs, cats, horses) will not be considered.